



Programme

**The TOPRA 42nd Spring Introductory Course:
Introduction to Pharmaceutical Regulatory Affairs**

31 Mar – 3 April 2020

Online

Tuesday 31 Mar 2020

Chairperson: Jayne Cook, *Abbvie Ltd*

- 08:30 **Registration online**
- 09:00 **Welcome & Introduction to the course**
Claire Beggs, GW Pharma & Samantha Alsbury, *TOPRA*
- 09:15 **New Product Development, The European Regulatory Environment & the Role of Regulatory Affairs**
Steve Brookes, *Biogen*
- 10:20 **Break**
- 10:35 **Overview of the MAA**
Jenny Lamport, *1st Regulatory Ltd.*
- 11:35 **Chemical Development/Quality**
Brian Corrigan, *MSD*
- 12:40 **Lunch**
- 13:25 **Pharmaceutical Development/Quality**
Brian Corrigan, *MSD*
- 14:30 **Module 3. An Agency Perspective**
Mirza Catibusic, *Health Products Regulatory Authority (HPRA)*
- 15:35 **Break**
- 15:50 **Case Study 1. Chemistry & Pharmacy**
Sally Steeden, *Biogen*
- 16:10 **Closing remarks of the day**
Jayne Cook, *Abbvie Ltd*

Wednesday 1 April 2020

Chairperson: Bob Ibbotson, *Lucis Consulting Ltd.*

- 08:30 **Registration online**
- 08:55 **Opening and learning objectives presentation**
Bob Ibbotson, *Lucis Consulting Ltd.*
- 09:00 **Understanding the Need for Non Clinical Safety Studies**
Chris Powell, *GlaxoSmithKline*
- 10:10 **The Importance of Pharmacokinetics & Pharmacodynamics in Drug Development**
Helen Walker, *HW ClinPharm Ltd*
- 11:15 **Break**
- 11:30 **The Components of the Non-Clinical Section of a Marketing Authorisation Application**
David Jones, *Medicines and Healthcare products Regulatory Agency (MHRA)*
- 12:40 **Lunch**
- 13:30 **Clinical Drug Development, Paediatric Investigation Plans & the link with Regulatory Affairs**
Steve Pinder, *Envestia Ltd*
- 14:45 **Break**
- 14:50 **The Regulation of Clinical Trials in Europe – An Agency Perspective**
Gunilla Nielson, *Medical Products Agency (MPA)*
- 15:45 **The European Clinical Trials Process – Industry Perspective**
Shaila Choi, *KKSC Solutions Ltd*
- 16:25 **Break**
- 16:30 **The MAA – the perspective of an EU Regulatory Authority Clinical Assessor**
Jan Span, *Medicines Evaluation Board (MEB)*
- 17:30 **Case Study 2. Non-Clinical & Clinical Development**
Ming Ewe, *Freeline*
- 17:45 **Closing remarks of the day**
Bob Ibbotson, *Lucis Consulting Ltd.*

Chairperson: Niamh Lawler-Turner, *PharmaFind Ltd*

- 08:30 **Registration online**
- 09:00 **Opening and learning objectives presentation**
Niamh Lawler-Turner, *PharmaFind Ltd*
- 09:05 **The Centralised Procedure - Practical Industry Experience**
Jenny Horwood, *Pfizer*
- 10:10 **The Mutual Recognition Procedure & the Decentralised Procedure – Practical Industry Experience**
Pete Embley, *Bionical EMAS*
- 11:15 **Break**
- 11:30 **EU Procedures and the Factors for Success – My Experience as a Pharmaceutical Assessor and Unit Manager**
Sue Harris, *ex-MHRA*
- 12:35 **Generic Applications & Biosimilars**
Pete Embley, *Bionical EMAS*
- 13:40 **Lunch**
- 14:30 **Regulatory Strategy Session Part 1:**
 1. Initial considerations – bigger picture & strategic thinking
 2. Information protection
 3. Think global
 4. Regulatory/HTA advice
David Kane, *Vertex Pharmaceuticals (Europe) Ltd*
- 15:30 **Break**
- 15:45 **Regulatory Strategy Session Part 2:**
 1. Paediatric development & PIPs
 2. Orphans
 3. Early access
 4. Tradenames
David Kane, *Vertex Pharmaceuticals (Europe) Ltd*
- 17:15 **Case Study 3. Regulatory Strategy**
David Kane, *Vertex Pharmaceuticals (Europe) Ltd*
- 17:30 **Closing remarks of the day**
Niamh Lawler-Turner, *PharmaFind Ltd*

Chairperson: Luis Casanova, *Shionogi*

- 08:30 **Registration online**
- 09:00 **Opening and learning objectives presentation**
Luis Casanova, *Shionogi*
- 09:05 **Lifecycle Management – Quality**
Isabel Zwart, *Biogen*
- 10:10 **Lifecycle Management - Safety & Efficacy**
Avni Pandhi, *Biogen*
- 11:15 **Break**
- 11:30 **Product Information – Regulation of the SmPC, PIL & label**
Julia Coombes, *MHRA*
- 12:50 **Accurate, Balanced, Clear? The ABC of Medicines Advertising**
Tannyth Cox, *Prescription Medicines Code of Practice Authority*
- 13:30 **Lunch**
- 14:15 **Health Technology Assessment: Why and where does the regulatory professional become involved?**
Sara Lopes, *Shionogi*
- 15:05 **An Introduction to Biotechnology & Advanced Therapy Medicinal Products**
Paul Smith, *MetisRA Consulting Ltd*
- 16:10 **Break**
- 16:15 **Case Study 4. Variations**
Sanna Dean, *Abbvie Ltd*
- 16:30 **Questions and closing remarks**
Luis Casanova, *Shionogi*